Biomarin Pharmaceutical INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
BioMarin Pharmaceutical Inc. has released its 2026 proxy statement detailing director elections, executive compensation, and a proposed amendment to its 2017 Equity Incentive Plan.
NASDAQ
BioMarin Pharmaceutical Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
BioMarin is asking stockholders to approve an amendment to its 2017 Equity Incentive Plan to increase the number of shares reserved for issuance.
NASDAQ
BioMarin Pharmaceutical Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
BioMarin Pharmaceutical Inc. has announced its Annual Meeting of Stockholders to be held on May 21, 2024, and provided updates on its 2023 financial performance and strategic priorities.